Cholesterol, lipids & cardiovascular risk
Cholesterol is not one number. A useful lipid assessment looks at the different particles carrying cholesterol and triglycerides through the blood, then places those results inside the wider cardiovascular picture.
Cholesterol is essential biology. The question is how it is being transported through the blood and what that means in context.
Cholesterol is used throughout the body, including in cell membranes and the production of steroid hormones.
Because cholesterol and other fats do not travel freely in blood, they are carried inside particles called lipoproteins.
This is why a lipid profile contains several measurements rather than one simple cholesterol result.
```Total cholesterol
The total amount of cholesterol carried within the different lipoprotein particles in the blood. Useful as part of the profile, but limited when interpreted alone.
LDL cholesterol
Measures the amount of cholesterol carried within low-density lipoprotein particles. LDL-related exposure is an important part of atherosclerotic cardiovascular risk.
HDL cholesterol
Measures cholesterol carried within high-density lipoprotein particles. It provides useful information, but should not be reduced to a simple assumption that higher is always better.
Triglycerides
A major form of circulating fat. Triglycerides can change with food intake, alcohol, metabolic health and other factors.
One number cannot describe the whole lipid picture.
Total cholesterol gives the overall amount of cholesterol circulating within lipoproteins in the blood.
It can be useful, but two people with the same total cholesterol can have very different LDL, HDL, triglyceride and non-HDL results.
This is why IMULAB does not interpret total cholesterol as a standalone measure of cardiovascular health.
The breakdown matters more than the headline number.
What does LDL cholesterol actually measure?
LDL cholesterol, usually written as LDL-C, measures the amount of cholesterol being carried within low-density lipoprotein particles.
LDL particles are part of a wider group of particles containing apolipoprotein B. When these particles enter and are retained within the artery wall, they can contribute to the development of atherosclerosis over time.
LDL-C is therefore an important part of cardiovascular risk assessment.
It should still be interpreted alongside age, blood pressure, smoking status, diabetes, kidney disease, family history and other relevant risk factors.
```HDL is more complicated than "good cholesterol".
HDL-C measures the amount of cholesterol carried within high-density lipoprotein particles.
Lower HDL cholesterol can be associated with higher cardiovascular risk in some contexts, but simply increasing the HDL-C number does not necessarily reduce risk.
Very high HDL should not automatically be assumed to be protective either.
IMULAB therefore treats HDL as part of the lipid profile rather than using it as a score of cardiovascular protection.
```Looking beyond LDL alone.
Non-HDL cholesterol is calculated by subtracting HDL cholesterol from total cholesterol.
It therefore captures the cholesterol carried within the broader group of potentially atherogenic lipoproteins rather than LDL alone.
This includes cholesterol carried in LDL and other apolipoprotein B-containing particles.
LDL-C tells us about cholesterol within LDL. Non-HDL widens the view to the cholesterol carried by the broader atherogenic particle population.
A different type of lipid.
Triglycerides are fats carried through the bloodstream and used as an energy source.
Their concentration can be influenced by recent food intake, alcohol, body composition, insulin sensitivity, genetics and other metabolic factors.
Elevated triglycerides can therefore add useful information to the wider cardiovascular and metabolic picture.
As with cholesterol, the result should not be interpreted in isolation.
```Cholesterol concentration tells us one thing. Particle biology can tell us something different.
Standard lipid profiles remain useful, but there are situations where additional measurements can add context.
Apolipoprotein B, apolipoprotein A1 and Lipoprotein(a) look at different aspects of lipoprotein biology and should not be treated as interchangeable versions of cholesterol.
These measurements may be particularly useful when someone has an unusual lipid pattern, a strong family history or a cardiovascular risk picture that is not fully explained by the standard lipid profile.
ApoB gives us a different view of atherogenic particles.
Apolipoprotein B, usually shortened to ApoB, is a structural protein found on the major atherogenic lipoprotein particles.
Because each of these particles carries ApoB, the concentration of ApoB can provide information about the number of circulating atherogenic particles rather than simply the amount of cholesterol contained within them.
This distinction can matter because two people with a similar LDL-C result do not necessarily have the same number of LDL and other ApoB-containing particles.
```The principal protein associated with HDL.
Apolipoprotein A1, or ApoA1, is the principal structural protein within HDL particles.
It provides a different measurement from HDL cholesterol itself.
ApoA1 may be used alongside ApoB and the wider lipid profile when a more detailed assessment of lipoprotein biology is required.
Ratios such as ApoB to ApoA1 can also be calculated, but IMULAB does not treat any single ratio as a substitute for assessment of the underlying results and overall cardiovascular risk.
```Lp(a) behaves differently from most lipid markers.
Lipoprotein(a), written as Lp(a), is a lipoprotein particle related to LDL but with an additional protein called apolipoprotein(a).
Higher Lp(a) is associated with increased cardiovascular risk and is now recognised as an important inherited risk factor.
Unlike LDL cholesterol or triglycerides, Lp(a) concentration is largely determined by genetics and tends to remain relatively stable throughout life.
That means the purpose of measuring Lp(a) is different. For many people, it is something worth establishing rather than a biomarker that needs to be repeatedly chased up and down.
Cholesterol is one part of cardiovascular risk.
Cardiovascular disease develops through the interaction of multiple risk factors over time.
Blood lipids are important, but they sit alongside other factors including age, blood pressure, smoking, diabetes, kidney function, family history and existing cardiovascular disease.
This is why a cholesterol result cannot be used on its own to tell someone their future cardiovascular risk.
In UK clinical practice, formal cardiovascular risk assessment brings several of these factors together.
A better lipid result does not make the rest of cardiovascular risk disappear. The whole picture still matters.
Not every lipid marker behaves the same way.
LDL cholesterol, non-HDL cholesterol and triglycerides can change with diet, weight change, medication, metabolic health and other factors.
Lp(a), on the other hand, is much more strongly determined by genetics.
Understanding this difference matters when deciding whether repeat testing is useful.
If an intervention has been made specifically to change LDL cholesterol or triglycerides, repeat testing can show whether the change has had the intended effect.
Repeatedly measuring a genetically stable marker without a specific reason may provide much less additional information.
```Keep repeat testing reasonably consistent.
Lipid measurements can be affected by the circumstances around testing, particularly triglycerides.
Some lipid testing can be performed without fasting, while particular panels or clinical circumstances may require specific preparation.
Follow the preparation instructions supplied with your IMULAB test rather than assuming that every cholesterol test has the same requirements.
Recent food intake can influence triglycerides more noticeably than some other lipid measurements.
Alcohol intake can influence triglycerides and should be considered when comparing results.
Acute illness can change lipid measurements and may make a result less representative of your usual baseline.
When tracking change, testing under reasonably similar conditions improves the value of the comparison.
The value is often in the direction of travel.
A single lipid profile shows where your results sit today.
Repeat testing can show whether LDL-C, non-HDL cholesterol, triglycerides or ApoB are stable, improving or moving in the wrong direction.
This becomes particularly useful after a deliberate change in diet, body composition, medication or other intervention.
Not every small change is meaningful. Biological and analytical variation exists.
The aim is to identify genuine trends rather than reacting to every small fluctuation.
```Look at particles, cholesterol and overall risk together.
Total cholesterol gives an overview, but it does not describe the whole lipid picture.
LDL-C, HDL-C, non-HDL cholesterol and triglycerides provide more detail.
ApoB can add information about the number of atherogenic lipoprotein particles, while Lp(a) can identify an additional largely inherited component of cardiovascular risk.
None of these results should be treated as a complete cardiovascular risk assessment on their own.
The strongest interpretation brings the lipid profile together with blood pressure, metabolic health, family history, smoking status, kidney function and previous results where available.
```Start with the question. Then choose the right depth of testing.
Advanced Heart Health
A more detailed cardiovascular blood assessment including cholesterol, apolipoproteins and additional cardiovascular markers.
Performance Baseline
Start here if you want cardiovascular markers interpreted alongside blood health, metabolic health, nutrition, hormones, thyroid function and the wider health and performance picture.